Hofheinz R, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life across three tumor types. Poster presented at the 2019 ESMO World Congress on Gastrointestinal Cancer Conference; July 2019. Barcelona, Spain.
Fizazi K, Shore ND, Tammela T, Kuss I, Le Berre M, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Smith MR. Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (PTS) with nonmetastatic castrate-resistant prostate cancer (NMCRPC). Presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31, 2019. Chicago, IL. [abstract] J Clin Oncol. 2019 Jun; 37(15_Suppl).
Kaye JA, Margulis AV, Fortuny J, McQuay LJ, Plana E, Bartsch JL, Bui CL, Perez-Gutthann S, Arana A. Cancer incidence after initiation of antimuscarinic medications for overactive bladder in the United Kingdom: evidence for protopathic bias. Pharmacotherapy. 2017 Jun;37(6):673-83. doi: 10.1002/phar.1932